Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
6.8M |
$129M |
$19.00 |
Jun 28, 2021 |
By Versant Venture Capital VI, L.P. |
Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
2.1M |
$39.9M |
$19.00 |
Jun 28, 2021 |
By Versant Vantage I, L.P. |
CRISPR Therapeutics AG |
Director |
Common Shares |
149K |
$9.3M |
$62.50 |
Jul 19, 2021 |
Indirect |
Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Stock Option (Right to Buy) |
47.1K |
|
|
Jun 23, 2021 |
Direct |
Black Diamond Therapeutics, Inc. |
Director, 10%+ Owner |
Stock Option (Right to Buy) |
15K |
|
|
Jun 18, 2021 |
Direct |
CRISPR Therapeutics AG |
Director |
Stock Option (Right to Buy) |
12K |
|
|
Jun 9, 2022 |
Direct |
Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Series A convertible preferred stock |
0 |
|
|
Jun 28, 2021 |
By Versant Capital VI, L.P. |
Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Series B convertible preferred stock |
0 |
|
$2.00 |
Jun 28, 2021 |
By Versant Capital VI, L.P. |
Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Series B convertible preferred stock |
0 |
|
$2.00 |
Jun 28, 2021 |
By Versant Vantage I, L.P. |
Monte Rosa Therapeutics, Inc. |
Director, 10%+ Owner |
Series C convertible preferred stock |
0 |
|
$2.96 |
Jun 28, 2021 |
By Versant Vantage I, L.P. |